Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 13
---
 into letter agreements, or the 2025 Warrant Agreements, with certain accredited holders, or Holders, of our outstanding Series E warrants, or the Series E Warrants, Series H warrants, or the Series H Warrants, Series J warrants, or the Series J Warrants, and Series K warrants, or the Series K Warrants, issued in prior transactions, pursuant to which the Holders agreed to exercise certain of such warrants in exchange for a reduction in exercise price of each warrant to $0.31 per share. An aggregate of 200,433 warrants were exercised for aggregate gross proceeds of approximately $62,000, before estimated offering expenses. We did not issue new warrants to replace the warrants that were exercised. eRapa Granted Orphan Drug Designation in Europe and Fast Track Designation On May 12, 2025, we announced that the European Commission had granted Orphan Drug Designation for eRapa in FAP. Orphan Drug Designation in the European Union is granted by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products. It is intended to encourage the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. If approved for marketing, this designation will provide 10 years of marketing exclusivity and also provide special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees. Contingent Liability As previously disclosed in the Notes to the Consolidated Unaudited Interim Financial Information for the six-month period ended June 30, 2025, we were involved in a dispute with a former advisor regarding fees. The dispute was resolved through a settlement, the terms of which included a payment made to the former advisor on September 29, 2025.

| 6 |

For more information
on recent developments with respect to eRapa, see “—Company Overview.”

Our Pipeline and Platform Technologies

We
are actively pursuing the development of eRapa in FAP and tolimidone in T1D. Due to resource constraints, MTX110 has been de-prioritized
in the three orphan brain cancer indications. Our development pipeline is as follows:

Corporate Information

We
are a public limited company incorporated under the laws of England and Wales under registered number 09216368. Our principal executive
offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone